Incyte has initiated a Phase I clinical trial of INCB13739, an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears
to be critical to the development of Type 2 diabetes.
The trial is a
double-blind, placebo-controlled, single- and multiple-dose-rising study designed
to assess the safety and pharmacokinetics of INCB13739 in healthy volunteers.
The program will also evaluate the ability of INCB13739 to inhibit 11beta-HSD1
activity in adipose tissue and liver of high-body mass index individuals. Preclinical
studies have shown that 11beta-HSD1 activity in these two tissues may be a primary
driver of insulin resistance and diabetes.
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
FDA Issues Warning Over Unapproved Breast Implant Device
The FDA said that the surgeon has been advertising the unapproved device on his web site.
FDA Recognizes Polish, Slovenian Inspections
Regulators on both sides of the Atlantic are optimistic they’ll meet the deadline, which they hope will allow them to direct more inspection resources elsewhere.
